Therapeutic Strategies for Mitigating Driving Risk in Patients with Narcolepsy
Catherine A McCall,1,2 Nathaniel F Watson3 1Department of Pulmonary, Critical Care, and Sleep Medicine, VA Puget Sound Health Care System, Seattle, WA, USA; 2Department of Psychiatry and Behavioral Sciences, University of Washington Sleep Medicine Center, Seattle, WA, USA; 3Department of Neurology,...
Guardado en:
Autores principales: | McCall CA, Watson NF |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4cf6b665b22d4c05ab537c2476f43dc4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immune-mediated comorbidities in Saudi patients with narcolepsy
por: Alomar M, et al.
Publicado: (2019) -
Assessing narcolepsy with cataplexy in children and adolescents: development of a cataplexy diary and the ESS-CHAD
por: Wang YG, et al.
Publicado: (2017) -
Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report
por: Pellitteri G, et al.
Publicado: (2020) -
Treatment paradigms for cataplexy in narcolepsy: past, present, and future
por: Swick TJ
Publicado: (2015) -
Narcolepsy Type 1: A Remitting Disease? An Unusual Case Report
por: Vellieux G, et al.
Publicado: (2021)